Clinical Report: Assessment of FangJiHuangQi Granules in Heart Failure Patients
Overview
This report outlines a randomized, placebo-controlled trial designed to evaluate the safety and efficacy of FangJiHuangQi Granules (FJHQG) in patients with heart failure (HF).
Background
Heart failure (HF) is a significant global health issue, affecting over 64 million individuals and imposing a substantial burden on healthcare systems. Traditional Chinese Medicine (TCM) has been utilized in HF management, with FangJiHuangQi decoction showing promise in alleviating symptoms. However, clinical evidence supporting the use of FJHQG in HF patients remains limited.
Data Highlights
This trial will recruit 100 patients with HF, randomly assigning them to either the intervention group receiving FJHQG or a control group receiving placebo alongside standard therapy. The primary outcome will be assessed through the six-minute walk test at week 24, with secondary outcomes including BNP levels, NYHA classification, and major adverse cardiovascular events (MACE).
Key Findings
The trial is a randomized, double-blind, placebo-controlled study.
100 patients with heart failure will be enrolled, with 50 in each group.
FJHQG will be administered for 12 weeks to the intervention group.
Primary outcome: changes in the six-minute walk test at week 24.
Secondary outcomes include BNP levels, NYHA classification, and MACE monitoring.
Exploratory assessments will include fluid balance, symptom scores, and echocardiograms.
Clinical Implications
The findings from this trial may provide valuable insights into the role of FJHQG as an adjunct therapy in heart failure management. If proven effective, FJHQG could enhance treatment options for patients with HF.
Conclusion
This study aims to rigorously assess the efficacy and safety of FangJiHuangQi Granules in heart failure patients.
